SUPPLEMENTAL DIGITAL CONTENT 2 – FIGURE 1

Randomly assigned 1:1 to RPV or EFV (N = 1368)

Randomly assigned to RPV N = 686
Received RPV N = 686

Discontinued n = 94 (13.7%)
Reasons for discontinuation:
  AE n = 23 (3.4%)
  Reached virologic endpoint n = 36 (5.2%)
  Lost to follow-up n = 15 (2.2%)
  Noncompliance n = 8 (1.2%)
  Consent withdrawn n = 6 (0.9%)
  Other reason n = 2 (0.3%)
  Ineligibility to continue trial n = 2 (0.3%)
  Sponsor’s decision n = 2 (0.3%)

Ongoing at Week 48 n = 592 (86.3%)

Randomly assigned to EFV N = 682
Received EFV N = 682

Discontinued n = 112 (16.4%)
Reasons for discontinuation:
  AE n = 53 (7.8%)
  Reached virologic endpoint n = 14 (2.1%)
  Lost to follow-up n = 15 (2.2%)
  Noncompliance n = 4 (0.6%)
  Consent withdrawn n = 18 (2.6%)
  Other reason n = 4 (0.6%)
  Ineligibility to continue trial n = 2 (0.3%)
  Sponsor’s decision n = 1 (0.1%)
  Failure to fulfil inclusion/exclusion criteria n = 1 (0.1%)

Ongoing at Week 48 n = 570 (83.6%)

AE = adverse event